



Resource impact summary report

Resource impact

Published: 11 March 2026

www.nice.org.uk

Contents

Resource impact summary report	3
Guidance recommendations	3
Financial and capacity resource impact.....	3
Eligible population for epcoritamab.....	3
Treatment options for the eligible population	4
Key information.....	4
About this resource impact summary report.....	4

Resource impact summary report

This summary report is based on the NICE assumptions used in the [resource impact template](#). Users can amend the 'Population and treatments' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Guidance recommendations

See [NICE's recommendations on epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment](#).

Financial and capacity resource impact

The key drivers of resource impact are:

- the average treatment duration of epcoritamab and comparators
- that epcoritamab is administered subcutaneously but most comparators are administered intravenously.

The company has a [commercial arrangement](#). This makes epcoritamab available to the NHS at a discount.

The payment mechanism for epcoritamab is determined by the responsible commissioner and depends on whether it is classified as high cost.

Eligible population for epcoritamab

Table 1 shows the population eligible for epcoritamab and the number of people who are expected to have epcoritamab in each of the next 3 years, excluding forecast population growth.

Table 1 Population expected to be eligible for and have epcoritamab in England

Eligible population and uptake	Number of people eligible for epcoritamab	Uptake for epcoritamab	Number of people starting epcoritamab each year
Current practice without epcoritamab	307	0%	0
Year 1	307	70%	215
Year 2	307	70%	215
Year 3	307	70%	215

Treatment options for the eligible population

Comparator treatments for the eligible population include various combinations of chemotherapy and rituximab-based treatment. The resource impact template includes rituximab with bendamustine, lenalidomide with rituximab, and obinutuzumab with bendamustine, all of which are administered intravenously. It also includes chlorambucil chemotherapy, which is administered orally. Epcoritamab is administered subcutaneously.

Key information

Table 2 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	PBC 02L
Commissioner	NHS England
Providers	NHS hospital trusts
Pathway position	3 rd line and later

About this resource impact summary report

This resource impact summary report accompanies the [NICE technology appraisal guidance on epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment](#) and should be read with it.

ISBN: 978-1-4731-9399-4